Active, not recruitingPhase 1NCT03465618

A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors

Studying Pituitary adenoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Nelson Moss, MD, M.D
Memorial Sloan Kettering Cancer Center
Intervention
89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging(drug)
Enrollment
17 enrolled
Eligibility
18 years · All sexes
Timeline
2018 – 2026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03465618 on ClinicalTrials.gov

Other trials for Pituitary adenoma

Additional recruiting or active studies for the same condition.

See all trials for Pituitary adenoma →

← Back to all trials